We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Astellas and Drais, through new virtual firm Tacurion, develop ASP7035
08 May 2013
Executive Summary
Once again, Astellas Pharma Inc. and Drais Pharmaceuticals Inc. (clinical-stage drug development) have signed an agreement for the development and commercialization of an Astellas compound, this time the Phase IIa-ready vasopressin V2 receptor selective agonist ASP7035 for nocturia (waking up at night to urinate). Astellas will transfer ownership of the compound to Tacurion Pharma Inc., a virtual company to be operated by Drais’ executive team.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Alliance
R&D and Marketing (Licensing)
Reverse Licensing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?